PUF60: A Potential Drug Target and Biomarker for Poly(U) Binding Splicing Factor 60

Target Name: PUF60

NCBI ID: G22827

PUF60

PUF60: A Potential Drug Target and Biomarker for Poly(U) Binding Splicing Factor 60

Poly(U) binding splicing factor 60 (PUF60) is a protein that plays a crucial role in the process of gene expression, specifically in the regulation of alternative splicing. Alternative splicing is a mechanism by which cells generate a variety of RNA isoforms from a single gene, which can lead to increased gene expression and organisms with a diverse range of functions. PUF60 is a key regulator of alternative splicing, ensuring that the most abundant isoform is produced and that the gene is properly expressed.

Recent studies have identified PUF60 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the biology of PUF60, its potential drug targets, and its role as a biomarker in disease diagnosis and treatment.

Biography of PUF60

PUF60 is a 21-kDa protein that belongs to the SPF/FAP domain family of proteins. It is expressed in most tissues and cells and is involved in various cellular processes, including cell growth, differentiation, and the regulation of gene expression.

PUF60 functions as a negative regulator of splicing by affecting the stability and translation of pre-mRNA species. It does this by interacting with the 4'-end of the pre-mRNA and preventing its processing by the splicing machinery. This interaction between PUF60 and splicing factors is critical for the regulation of alternative splicing and the production of the most abundant RNA isoform.

Potential Drug Targets

PUF60 has been identified as a potential drug target due to its involvement in various diseases. Its functions in cancer, neurodegenerative diseases, and developmental disorders have been implicated in the regulation of gene expression and the production of misfolded proteins, which can lead to the development of these diseases.

In cancer, PUF60 has been shown to play a role in the regulation of cell cycle progression and the production of cancer-associated intracellular signaling pathways. It has also been shown to promote the formation of multinucleosomefolds, which are a hallmark of cancer-induced cell transformation.

In neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, PUF60 has been implicated in the regulation of neurotransmitter synthesis and the production of misfolded proteins that cause neurodegeneration.

In developmental disorders, such as Down syndrome, PUF60 has been shown to play a role in the regulation of chromosomal stability and the production of normal proteins.

Potential Biomarkers

PUF60 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be decreased in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This decrease in PUF60 expression may indicate that these diseases are characterized by a dysfunction in the regulation of splicing and the production of RNA isoforms.

In addition,PUF60 has been shown to be a more stable protein than its splice variants, which may indicate that it is a more reliable biomarker for disease than its splice variants.

Conclusion

PUF60 is a protein that plays a critical role in the regulation of alternative splicing and has been identified as a potential drug target and biomarker for various diseases. Its functions in cancer, neurodegenerative diseases, and developmental disorders have been implicated in the regulation of gene expression and the production of misfolded proteins.

Further research is needed to fully understand the role of PUF60 as a drug target and biomarker for various diseases. Its potential as a drug target and biomarker may lead to the development of new treatments for these diseases.

Protein Name: Poly(U) Binding Splicing Factor 60

Functions: DNA- and RNA-binding protein, involved in several nuclear processes such as pre-mRNA splicing, apoptosis and transcription regulation. In association with FUBP1 regulates MYC transcription at the P2 promoter through the core-TFIIH basal transcription factor. Acts as a transcriptional repressor through the core-TFIIH basal transcription factor. Represses FUBP1-induced transcriptional activation but not basal transcription. Decreases ERCC3 helicase activity. Does not repress TFIIH-mediated transcription in xeroderma pigmentosum complementation group B (XPB) cells. Is also involved in pre-mRNA splicing. Promotes splicing of an intron with weak 3'-splice site and pyrimidine tract in a cooperative manner with U2AF2. Involved in apoptosis induction when overexpressed in HeLa cells. Isoform 6 failed to repress MYC transcription and inhibited FIR-induced apoptosis in colorectal cancer. Isoform 6 may contribute to tumor progression by enabling increased MYC expression and greater resistance to apoptosis in tumors than in normal cells. Modulates alternative splicing of several mRNAs. Binds to relaxed DNA of active promoter regions. Binds to the pyrimidine tract and 3'-splice site regions of pre-mRNA; binding is enhanced in presence of U2AF2. Binds to Y5 RNA in association with RO60. Binds to poly(U) RNA

The "PUF60 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PUF60 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets